Venclexta 50 MG tablet UD 7S
Ended Awarded Last action
- Contract number
- SPE2DR26F9ND5
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,306
Award facts
- Contract value 100% obligated
- $1,305.66 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded on January 27, 2026, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, covers the supply of VENCLEXTA 50 MG tablets in unit-dose packaging of seven tablets, with a ceiling value of $1,305.66 and a firm fixed-price structure. The award is not set-aside and represents a competitive procurement under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999.00 vehicle established through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving critical federal medical procurement needs for military and veteran healthcare systems. The parent company, Cencora, Inc. (doing business as AmerisourceBergen), maintains an additional substantial IDC with the DLA valued at up to $999,999,999.00 through December 31, 2031, demonstrating the company's long-standing role in supporting the Department of Defense's pharmaceutical supply chain.
This procurement exemplifies the DLA's reliance on prime pharmaceutical vendors to deliver specialty medications to military treatment facilities and healthcare programs worldwide. VENCLEXTA is an oncology medication used in the treatment of certain blood cancers, reflecting the DLA's need for comprehensive access to brand-name pharmaceuticals across multiple therapeutic domains. The delivery order maintains the firm fixed-price structure typical of DLA pharmaceutical procurement, with performance required by February 18, 2026, ensuring timely supply of critical medications to federal healthcare beneficiaries.
Quick answers
Who was awarded contract SPE2DR26F9ND5?
SPE2DR26F9ND5 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26F9ND5 worth?
The government has obligated $1,306 on SPE2DR26F9ND5.
Is contract SPE2DR26F9ND5 an order under another contract?
Yes. SPE2DR26F9ND5 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9ND5 competed?
The extent of competition for SPE2DR26F9ND5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award